Top Private Equity News, Member Posts, Managed Futures Daily Indices and more!

2yrs ago Private Equity privateequitywire Views: 772

Sheridan Capital Partners invests in SimiTree Healthcare Consulting

Submitted 19/05/2021 - 9:04am

Sheridan Capital Partners (Sheridan) has invested in SimiTree Healthcare Consulting (SimiTree), a strategic and equal combination of Simione Healthcare Consultants (Simione) and BlackTree Healthcare Consulting (BlackTree). 

SimiTree will help post-acute healthcare organisations achieve clinical and financial excellence through consulting, outsourcing, and talent solutions. Sheridan invested alongside SimiTree’s management team, who have retained meaningful ownership in the business.
 
In addition to financial, clinical and operational consulting, SimiTree will offer clients a robust suite of services, including outsourced billing, coding and revenue cycle management; executive recruiting, interim staffing and other talent solutions; guidance through mergers and acquisitions; sales consulting and education; and data analytics. 

“We are excited to join forces with Sheridan to help bring these two great companies together to drive continued growth with our complementary service offerings,” says Mike Freytag, Managing Principal of SimiTree.
 
“We have significant conviction in the long-term trends in the post-acute market,” says Sean Dempsey, Partner at Sheridan Capital Partners. “We’ve long been impressed with the work of Simione, BlackTree and their accomplished teams.”
 
Sheridan will work with SimiTree’s management team to invest significantly in technology, talent, and acquisitions of other businesses serving the post-acute market. “The transformative partnership with Sheridan will allow the Company to expand its capabilities and scale rapidly while continuing to deliver key services and solutions to clients,” said David Berman, Managing Principal of SimiTree. 
 
“Sheridan is pleased to partner with SimiTree to support the new company as it scales, delivering an excellent experience to even more post-acute healthcare organisations,” says Chris McCrory, Principal at Sheridan.
 
The transaction was led by Sean Dempsey, Jonathan Lewis, Chris McCrory, Matt Hinshaw and Addison Jones at Sheridan Capital Partners. Twin Brook Capital Partners provided debt financing for the transaction. McDermott Will & Emery LLP served as legal counsel to Sheridan Capital Partners. Brentwood Capital Advisors LLC and Robinson & Cole LLP served as financial advisor and legal counsel, respectively, to the Company. Financial terms of the transaction were not disclosed.
 

Like this article? Sign up to our free newsletter Tags Deals & Transactions Healthcare & Life Sciences Investments

Today's Private Equity Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.